Given that previous studies had focused on the assessment of the efficacy of first-generation EGFR-TKIs in comparison with platinum-doublet therapy in EGFR-mutated NSCLC, a multicenter, randomized phase III trial (WJOG 5108L) was designed to directly compare erlotinib with gefitinib for the treatment of advanced lung adenocarcinoma, regardless of the EGFR mutation status [21]. Here, EGFR is linked to lung adenocarcinoma.